Glenmark Pharma gains as its arm launches Adapalene Gel USP in new pump packs
Glenmark Pharmaceuticals is currently trading at Rs. 2286.65, up by 5.05 points or 0.22% from its previous closing of Rs. 2281.60 on the BSE.
The scrip opened at Rs. 2316.85 and has touched a high and low of Rs. 2316.85 and Rs. 2277.05 respectively. So far 4450 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2536.85 on 28-Aug-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.
Last one week high and low of the scrip stood at Rs. 2413.40 and Rs. 2273.70 respectively. The current market cap of the company is Rs. 65038.68 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.
Glenmark Pharmaceuticals’ subsidiary -- Glenmark Therapeutics Inc., USA, (Glenmark) has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin Gel, 0.1%. According to Nielsen syndicated data for the latest 52-week period ending September 5, 2026, the Differin Gel, 0.1% (OTC) market achieved annual sales of around $45.8 million.
